XENE — Xenon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $3.16bn
- $2.44bn
- 57
- 27
- 59
- 45
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.83 | 32.2 | 18.4 | 9.43 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 49.6 | 64.5 | 97.4 | 139 | 214 |
Operating Profit | -42.8 | -32.3 | -79 | -129 | -214 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -41.6 | -29.1 | -78.9 | -125 | -183 |
Provision for Income Taxes | |||||
Net Income After Taxes | -41.6 | -28.8 | -78.9 | -125 | -182 |
Net Income Before Extraordinary Items | |||||
Net Income | -41.6 | -28.8 | -78.9 | -125 | -182 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -40 | -28 | -77.1 | -125 | -182 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.54 | -0.792 | -1.77 | -2.06 | -2.73 |